MBX Biosciences, Inc. announced on September 24, 2025, the pricing of its upsized public offering of 11,108,055 shares of common stock at a price of $18.00 per share. The gross proceeds to the company from the offering are expected to be $199.9 million, before deducting underwriting discounts and other offering expenses.
The company also granted the underwriters a 30-day option to purchase up to an additional 1,666,208 shares of common stock at the public offering price. The offering is expected to close on September 26, 2025, subject to customary closing conditions.
This successful pricing of an upsized offering provides MBX Biosciences with substantial capital to fund its operations and advance its pipeline of precision peptide therapies. While the offering results in dilution for existing shareholders, the upsized nature indicates strong investor demand, reflecting confidence in the company's prospects following recent positive clinical data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.